Generation of Neural Progenitor Cells Overexpressing Alzheimer’s Disease Genes with Familial Mutations and Analysis of Pathological Changes of Alzheimer’s Cells in Vivo


We seek to evaluate the impact of candidate AD drugs on Abeta and tau pathology in human cellular AD models. In collaboration with Dr. Tanzi’s laboratory (Massachusetts General Hospital), we will test the impact of select candidate AD drugs on both Abeta and tau pathology in the 30 human neural cell culture models developed in Aim 4. In the first year, we found that SGSM41i, a candidate AD drug designed to specifically decrease the toxic Abeta42 generation, decreases not only the Abeta plaques but also the tau pathology in the 30 human cellular AD models. In the second year, we will test additional anti-Abeta drugs, including SGSM36, SGSM46 and SGSM49, which showed the higher potency in decreasing toxic Abeta species in vitro. We will test additional candidate AD drugs designed to block Abeta or Abeta-induced neuronal toxicity in the 30 human neural cell culture models. The overarching goal of this aim is to set up a unified platform that can be used for both studying the pathogenic mechanism of AD and evaluating target-based candidate AD drugs before human clinical trials.

Funding to Date



Foundational, Production of New Animal/Cellular Models of AD


Doo Yeon Kim, Ph.D.

Related Content:

Systematic Assessment of Tandem Repeats in Alzheimer’s Disease (STaR-AD) Lars Bertram Valerija Dobricic 2024-02-28 Interpreting Alzheimer’s Disease-Associated Genetic Variation at Enhancer Regions Andreas R. Pfenning 2024-02-01 Moving the Cure Alzheimer’s Fund Genome Project Beyond Simple Associations: Integrating Functional Information, Fine-Mapping and Causal Inference Approaches into the Family-Based Analysis of the Cure Alzheimer’s Fund Whole-Genome Sequencing (WGS) Family Study Christoph Lange 2024-02-01 Exploring Novel Drug Candidates for Alzheimer’s Disease Through Integrative Pathway Analysis and Validation in 3D Cellular Models Doo Yeon Kim Luisa Quinti 2024-02-01 Characterization and Validation of Two Recently Created Sheep Models of Alzheimer’s Disease in Preparation for Use as a Preclinical Pharmaceutical Testing Model Russell G. Snell Natasha McKean 2024-01-31 Utility of Blood-Based Markers for Predicting Amyloid-Related Imaging Abnormalities and Their Course in Mild Cognitive Impairment and Alzheimer’s Disease Subjects Undergoing Routine Clinical Treatment with Amyloid-Directed Antibodies P. Murali Doraiswamy 2024-01-12 Growth, Characterization and Distribution of a Neurodegenerative Disease-Focused Fibroblast/iPS Cell Bank to Support Molecular Models of Patient-Specific Variation with Validation in Matched Donated Brain Tissues Derek H. Oakley 2023-12-08 Multidisciplinary Phenotyping of a Novel Humanized LOAD Mouse Model Giuseppina Tesco 2023-10-25